Does Medicare Cover Zepbound for Sleep Apnea?

Medicare Part D may cover Zepbound for sleep apnea when it is prescribed for the FDA-approved indication: moderate-to-severe obstructive sleep apnea in an adult with obesity. Coverage is not automatic. The person's Part D or Medicare Advantage drug plan may still apply its formulary, prior authorization, quantity, and pharmacy rules ^{1 2}.

It helps to separate five questions that are often blurred together:

1. FDA eligibility: Does the prescription match the approved sleep apnea indication?
2. Clinical appropriateness: Does the prescriber think tirzepatide is suitable and safe for this person?
3. Part D coverability: Is the drug being prescribed for a use that can be covered under the Part D benefit?
4. Plan authorization: Does the member's plan include or approve this particular prescription?
5. Personal cost: What does the plan charge at the pharmacy the member will use?

A "yes" at one step does not answer the next one.

Why the sleep apnea indication changes the Medicare answer

Federal Part D rules exclude drugs when they are used for weight loss. CMS also explains that a drug excluded when used for one purpose may be coverable when it is used to treat a different, non-excluded condition and otherwise meets Part D requirements ³.

That distinction now matters for Zepbound. CMS identifies moderate-to-severe obstructive sleep apnea as an indication eligible for Part D coverage. A Zepbound prescription for OSA therefore follows the member's Part D coverage process rather than being treated as a weight-loss-only prescription ¹.

Eligible for Part D coverage does not mean every plan must place Zepbound on its formulary or approve every request. It means the sleep apnea use is not automatically disqualified by the statutory exclusion for weight-loss drugs.

The Medicare GLP-1 Bridge is a separate route

The temporary Medicare GLP-1 Bridge provides certain eligible beneficiaries with GLP-1 medicines for weight management outside the Part D benefit. Current CMS guidance says that a person with moderate-to-severe OSA should obtain a GLP-1 prescribed for that condition through Part D and is not eligible for the Bridge on the basis of that OSA diagnosis, even if the person's plan does not currently cover the drug ¹.

This means the Bridge's advertised weight-management copay is not a guaranteed price for a Zepbound prescription submitted to Part D for OSA. The two routes have different eligibility, processing, and cost rules.

Which part of Medicare handles Zepbound?

Original Medicare Part A and Part B do not provide ordinary retail coverage for most medicines a person gives themselves. Part B covers a limited set of outpatient drugs, usually under specific circumstances such as administration by a medical provider. Part D covers many outpatient prescriptions that Part B does not ⁴.

In practice, the relevant coverage is usually:

• a stand-alone Part D plan for someone with Original Medicare
• the Part D component of a Medicare Advantage plan, often called an MA-PD plan

Not every Medicare Advantage plan includes drug coverage. Having Original Medicare, Medicare Advantage, or a Zepbound prescription by itself does not establish that the drug is covered. Check the exact drug plan listed on the member card.

What the FDA actually approved

On December 20, 2024, the FDA approved Zepbound, whose active ingredient is tirzepatide, to treat moderate-to-severe obstructive sleep apnea in adults with obesity. The approved use is in combination with a reduced-calorie diet and increased physical activity ^{5 6}.

The OSA indication does not include:

• mild OSA
• central sleep apnea without qualifying obstructive sleep apnea
• children
• adults who are only overweight rather than having obesity
• using the drug solely for weight reduction

The pivotal OSA studies enrolled adults with an apnea-hypopnea index (AHI) of at least 15 events per hour and a body mass index of at least 30 kg/m². Those were study eligibility criteria. A plan may translate the label into its own documentation requirements, but no universal Zepbound prior authorization rule applies to every Part D plan ⁶.

FDA eligibility is also not the same as clinical suitability. A prescriber still has to consider the person's health conditions, other medicines, previous treatment, likely benefit, and safety risks.

How strong is the evidence for OSA?

The FDA decision was supported by two 52-week, randomized, double-blind trials involving 469 adults with obesity and moderate-to-severe OSA. One trial enrolled people who were unable or unwilling to use positive airway pressure (PAP). The other enrolled people who were using PAP ⁷.

Participants received the maximum tolerated dose of 10 or 15 mg tirzepatide or placebo, alongside nutrition and physical-activity counseling. At week 52:

• In the trial without PAP use at baseline, AHI fell by an average of 25.3 events per hour with tirzepatide and 5.3 with placebo. The estimated difference was 20.0 fewer events per hour.
• In the trial involving PAP users, AHI fell by 29.3 events per hour with tirzepatide and 5.5 with placebo. The estimated difference was 23.8 fewer events per hour.
• The combined outcome of remission or mild OSA without excessive daytime sleepiness was reached by 42.2% of tirzepatide participants versus 15.9% of placebo participants in the first trial, and 50.2% versus 14.3% in the second ^{7 6}.

These are meaningful group averages, not a promise that one person will reach remission. The trials excluded people with type 2 diabetes, lasted 52 weeks, and were sponsored by Eli Lilly, the manufacturer. They measured AHI and several other physiological and patient-reported outcomes, but they were not designed to prove that Zepbound prevents heart attack or stroke, cures OSA permanently, or lets a person stop PAP ⁷.

How to check a specific plan before the prescription is filled

Start with the member's current plan documents or member portal, not a general online statement that "Medicare covers Zepbound." Check:

1. Is Zepbound on the current formulary?
2. Is it covered for OSA, and is prior authorization required?
3. Does the plan publish a Zepbound-specific authorization form or clinical criteria?
4. Are there step-therapy or quantity limits?
5. Does coverage differ by pen, vial, strength, or days' supply?
6. Which in-network or preferred pharmacies can dispense the covered formulation?
7. What will the member pay before and after the deductible?

Medicare drug plans can use prior authorization, step therapy, and quantity limits. They can also use prior authorization when a drug is covered for some medical conditions but not others. Some plans cover prescriptions only at in-network pharmacies, and a preferred in-network pharmacy may have lower cost sharing ^{2 8}.

What a prior authorization may need to show

The exact plan criteria control. A useful submission may include:

• the OSA diagnosis and its severity
• the relevant sleep-study report and AHI
• current height, weight, and BMI documentation
• the prescribed indication, formulation, strength, and days' supply
• current OSA treatment, including PAP use or the clinical reason it is not being used
• the prescriber's explanation of why Zepbound is appropriate
• any treatment history specifically requested by the plan

Do not add generic claims about failed treatments if the plan does not ask for them or the record does not support them. The most efficient request answers the actual criteria and attaches the records that verify those answers.

Why the requested dose can matter to authorization

The current prescribing information starts Zepbound at 2.5 mg once weekly for four weeks. It then increases to 5 mg, with further 2.5 mg increases after at least four weeks at the current dose. The labeled maintenance doses for OSA are 10 or 15 mg once weekly. The 2.5 mg dose is for starting treatment, not maintenance ⁶.

This information is not a personal dosing instruction. It matters to coverage because an authorization or quantity limit may need to account for starter strengths, escalation, and the eventual maintenance strength. The prescriber and plan should resolve a mismatch rather than the patient changing the dose.

What to do after a denial

First, ask the plan or pharmacy for the exact reason. "Not covered" can mean several different things:

• no prior authorization was submitted
• the request did not document the covered OSA indication
• the drug is not on the formulary
• the requested strength, formulation, or quantity conflicts with a plan rule
• the plan says a clinical criterion was not met
• the pharmacy is outside the network

A missing document or incorrect claim code may be fixable without arguing the medical merits. A formulary exclusion or clinical denial may require a coverage determination or exception.

Medicare allows the member or prescriber to ask the plan for an exception to cover a non-formulary drug or waive certain coverage rules. The prescriber must provide a supporting statement explaining the medical reason, such as why the plan's alternative would be less effective or would cause adverse effects ².

If the plan denies the request, follow the instructions and deadline in the written denial notice to request a redetermination. A fast request or appeal is reserved for a situation in which waiting for the standard decision could seriously jeopardize the person's life, health, or ability to regain maximum function ⁹.

What will Zepbound cost with Medicare?

There is no dependable nationwide answer. What a member pays can depend on:

• whether the plan approves the prescription
• the drug's formulary tier
• deductible status
• copayment or coinsurance
• the formulation and days' supply
• use of a preferred, standard, or out-of-network pharmacy
• eligibility for Extra Help or another assistance program

Medicare's Plan Finder can estimate monthly and annual drug costs after a person enters their prescriptions, but the member should still confirm the OSA coverage rule and current price with the plan. Extra Help can reduce Part D premiums, deductibles, coinsurance, and other prescription costs for people who qualify ^{10 11}.

A manufacturer savings offer or cash price is not the same as Part D coverage. Terms, eligible formulations, and prices can change. Medicare warns that drugs bought with discount cards instead of the Medicare plan do not count toward the Part D deductible or out-of-pocket maximum ¹¹.

Zepbound does not make OSA follow-up optional

Weight loss and better symptoms do not prove that airway obstruction has resolved. A person can feel better and still have clinically important breathing events during sleep.

The American Academy of Sleep Medicine says follow-up polysomnography or a home sleep apnea test may be used after clinically significant weight gain or loss. It also recommends follow-up testing to assess response to a non-PAP intervention ¹².

Keep using PAP or another prescribed OSA treatment unless the treating clinician changes the plan. A decision to reduce or stop PAP should be based on the clinical picture and, when appropriate, objective reassessment, not weight change or symptom improvement alone.

Safety questions belong in the decision too

Zepbound has a boxed warning because tirzepatide caused thyroid C-cell tumors in rats. It is not known whether it causes these tumors in humans. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or a previous serious hypersensitivity reaction to tirzepatide or its ingredients ⁶.

Common adverse effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and other gastrointestinal symptoms. Important warnings include severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis, hypoglycemia, and pulmonary aspiration during general anesthesia or deep sedation. Tirzepatide can delay gastric emptying and affect absorption of some oral medicines. Pregnancy is another major safety consideration because the label says Zepbound may cause fetal harm ⁶.

Tell the prescriber about all medicines, diabetes treatment, digestive disease, kidney or gallbladder problems, a history of pancreatitis, pregnancy or plans for pregnancy, and any planned operation or procedure. Zepbound should not be combined with another tirzepatide-containing product or a GLP-1 receptor agonist.

Questions to bring to the prescriber and plan

Ask the prescriber:

• Does my sleep study meet the moderate-to-severe OSA indication?
• Do my records establish obesity and support the prescription?
• Is Zepbound clinically appropriate with my conditions and medicines?
• What OSA treatment should I continue while the medicine is started?
• How and when will we reassess symptoms, weight, AHI, and PAP needs?

Ask the plan:

• Is Zepbound covered for the FDA-approved OSA indication under my current Part D benefit?
• What exact prior authorization criteria and form apply?
• Which formulation, strength, quantity, and pharmacy are covered?
• What records were missing if my request was denied?
• What is my cost at a preferred in-network pharmacy?
• How do I request an exception or appeal this decision?

The most accurate answer is therefore conditional: Zepbound can be Part D-coverable for moderate-to-severe OSA in an adult with obesity, but the person's plan must still approve the prescription, and the treating clinician must decide that it is appropriate.